CN113164631A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN113164631A
CN113164631A CN201980077048.3A CN201980077048A CN113164631A CN 113164631 A CN113164631 A CN 113164631A CN 201980077048 A CN201980077048 A CN 201980077048A CN 113164631 A CN113164631 A CN 113164631A
Authority
CN
China
Prior art keywords
compound
formula
therapeutically effective
effective amount
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980077048.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·A·阿穆尔
R·梅斯曼
迈克·萨瑟克格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Priority to CN202510991493.8A priority Critical patent/CN121154858A/zh
Priority to CN202510991492.3A priority patent/CN121338051A/zh
Priority to CN202510991495.7A priority patent/CN121130116A/zh
Publication of CN113164631A publication Critical patent/CN113164631A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980077048.3A 2018-09-21 2019-09-20 治疗癌症的方法 Pending CN113164631A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202510991493.8A CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991492.3A CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991495.7A CN121130116A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202510991492.3A Division CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991495.7A Division CN121130116A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991493.8A Division CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN113164631A true CN113164631A (zh) 2021-07-23

Family

ID=69887889

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201980077048.3A Pending CN113164631A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991493.8A Pending CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991495.7A Pending CN121130116A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991492.3A Pending CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510991493.8A Pending CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991495.7A Pending CN121130116A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991492.3A Pending CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Country Status (9)

Country Link
US (1) US20220125957A1 (https=)
EP (1) EP3852816A4 (https=)
JP (2) JP2022501441A (https=)
KR (1) KR20210095620A (https=)
CN (4) CN113164631A (https=)
AU (2) AU2019345320B2 (https=)
CA (1) CA3112806A1 (https=)
IL (2) IL281600B2 (https=)
WO (1) WO2020061458A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
KR20240004205A (ko) 2020-07-13 2024-01-11 포인트 바이오파마 인코포레이티드 방사성의약 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
SG11202005511VA (en) * 2017-12-13 2020-07-29 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636924A (zh) * 2013-10-18 2016-06-01 德国癌症研究中心 前列腺特异性膜抗原(psma)的标记的抑制剂，它们作为显影剂和用于治疗前列腺癌的药剂的用途
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AXEL BRÄUER等: "177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer", 《EUR J NUCL MED MOL IMAGING》 *
CLEMENS KRATOCHWIL等: "225Ac-PSMA-617 for PSMA-Targeted a-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer", 《THE JOURNAL OF NUCLEAR MEDICINE》 *
HOJJAT AHMADZADEHFAR等: "Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617", 《EUR J NUCL MED MOL IMAGING》 *
KAMBIZ RAHBAR等: "Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer", 《EUR J NUCL MED MOL IMAGING》 *

Also Published As

Publication number Publication date
WO2020061458A1 (en) 2020-03-26
JP2024178159A (ja) 2024-12-24
AU2019345320B2 (en) 2025-12-11
IL281600B2 (en) 2026-03-01
IL281600B1 (en) 2025-11-01
CN121154858A (zh) 2025-12-19
IL281600A (en) 2021-05-31
KR20210095620A (ko) 2021-08-02
EP3852816A1 (en) 2021-07-28
CN121338051A (zh) 2026-01-16
AU2026201845A1 (en) 2026-04-02
EP3852816A4 (en) 2022-07-13
CN121130116A (zh) 2025-12-16
IL323981A (en) 2025-12-01
JP2022501441A (ja) 2022-01-06
CA3112806A1 (en) 2020-03-26
AU2019345320A1 (en) 2021-04-22
US20220125957A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US20250235466A1 (en) Methods of treating cancer
AU2019345320B2 (en) Methods of treating cancer
JP7429688B2 (ja) シールド剤およびそれらの使用
CN109789207A (zh) 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物
RU2825637C2 (ru) Способы лечения рака
RU2811406C2 (ru) Способы лечения рака
HK40047004A (en) Methods of treating cancer
WO2017205447A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound
WO2024249352A1 (en) Methods for treating sstr positive cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination